Where AI is already paying off in drug development - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Where AI is already paying off in drug development

Pharmaceutical leaders point to faster manufacturing, smarter antibody design, and deeper data analysis.

  • By

  • Doug Brunk

  • September 9, 2026

  • 5 min

Share

Clinical Scorecard: Where AI is already paying off in drug development

At a Glance

CategoryDetail
ConditionPharmaceutical Development
Key MechanismsUtilization of AI for drug manufacturing, design, and data analysis.
Target PopulationPharmaceutical companies and healthcare systems.
Care SettingPharmaceutical development and research environments.

Key Highlights

  • AI enhances efficiency in drug manufacturing and candidate design.
  • Generative AI has limitations and cannot replace scientific expertise.
  • AI tools can analyze complex data and improve drug design processes.
  • Machine learning models can address specific challenges like viscosity in antibodies.
  • Internal expertise is crucial for evaluating AI tools and strategies.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • Generative AI can produce confident but incorrect results.
        • Understanding the limitations of AI systems is essential.

        Patient & Prescribing Data

        Patients requiring advanced pharmaceutical therapies.

        AI can expedite the development of effective drug candidates.

        Clinical Best Practices

        • Combine in-house and external AI tools for optimal results.
        • Develop a core team with expertise in machine learning and data management.
        • Use AI to challenge assumptions and recognize biases in research.

        Related Resources & Content

          Original Source(s)

          Where AI is already paying off in drug development

          • by Doug Brunk

          • September 9, 2026

          Related Content

          Enterovirus diversity may limit treatment advances

          Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.

          Rheumatoid arthritis tied to birth outcomes

          Researchers examine pregnancy outcomes and factors associated with preterm delivery and fetal size.

          FDA Approves Atacicept for IgA Nephropathy

          The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.